Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Return on Capital Employed (2021 - 2024)

Immuneering (IMRX) has 4 years of Return on Capital Employed data on record, last reported at 0.94% in Q3 2024.

  • For Q3 2024, Return on Capital Employed fell 44.0% year-over-year to 0.94%; the TTM value through Sep 2024 reached 0.94%, down 44.0%, while the annual FY2023 figure was 0.56%, 18.0% down from the prior year.
  • Return on Capital Employed reached 0.94% in Q3 2024 per IMRX's latest filing, down from 0.8% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.21% in Q4 2021 and bottomed at 0.94% in Q3 2024.
  • Average Return on Capital Employed over 4 years is 0.48%, with a median of 0.49% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: fell -11bps in 2022, then crashed -44bps in 2024.
  • A 4-year view of Return on Capital Employed shows it stood at 0.21% in 2021, then plummeted by -103bps to 0.43% in 2022, then tumbled by -35bps to 0.58% in 2023, then crashed by -61bps to 0.94% in 2024.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.94% in Q3 2024, 0.8% in Q2 2024, and 0.66% in Q1 2024.